Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

The role of hypoxia, vascular endothelial injury, and thrombotic inflammation in worsening
COVID-19 symptoms has been generally recognized. Damaged vascular endothelium plays …

Despite the emergence of high quality randomized trial data with the use of antithrombotic
agents to reduce the risk of thromboembolism, end‐organ failure, and possibly mortality in …

COVID-19 is associated with endothelial activation in the setting of a potent inflammatory
reaction and a hypercoagulable state. The end result of this thromboinflammatory state is an …

Abstract Coronavirus disease 2019 (COVID-19) associated coagulopathy is multifactorial
and involves inflammation driven hypercoagulability, endothelial dysfunction, platelet …

Coronavirus disease 2019 (COVID-19) has been shown to be strongly associated with
increased risk for venous thromboembolism events (VTE) mainly in the inpatient but also in …

Early in the coronavirus disease 2019 (COVID-19) pandemic, global governing bodies
prioritized transmissibility-based precautions and hospital capacity as the foundation for …

Abstract Coronavirus disease-19 (COVID-19) includes a thromboinflammatory syndrome
that may manifest with microvascular and macrovascular thrombosis. Patients with COVID …

Patients with COVID-19 often have hypoxemia, impaired lung function, and abnormal
imaging manifestations in acute and convalescent stages. Alveolar inflammation, pulmonary …

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the
COVID-19 pandemic in 2020 created unprecedented global challenges to existing models …